ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Abiraterone Acetate

Also written as “Abiraterone acetate”, “Abiraterone” and “abiraterone acetate”.

Its studies are mostly in Prostatic Neoplasms · Neoplasm Metastasis · Breast Neoplasms · Bulbo-Spinal Atrophy, X-Linked · Prostatic Neoplasms, Castration-Resistant, led by 8 companies.

Drug pageAbiraterone Acetate: every studyMany companies study it; this page follows only the 53 they lead. All 127 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 27, 201553 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only414 open or runningphase 4since Mar 27, 2015May 11, 2007none ahead
Jiangsu HengRui Medicineits history only32 open or runningphase 2since Apr 25, 2021Apr 25, 2021Dec 2026phase 2 · NCT06568094
Sun Pharmaceutical Industriesits history only31 open or runningphase 2since Mar 25, 2016Mar 25, 2016Dec 31, 2027phase 2 · NCT05422911
Sanofi20 open or runningphase 4since Jun 26, 2015Jan 4, 2012none ahead
Boryung Pharmaceuticalits history only10 open or runningphase 1since May 12, 2021May 12, 2021none ahead
Sino Biopharmaceuticalits history only10 open or runningphase 3since Aug 11, 2019Aug 11, 2019none ahead
Sumitomo Pharmaits history only10 open or runningphase 1since Dec 7, 2020Dec 7, 2020none ahead
Zentiva, k.s.its history only10 open or runningphase 1since Mar 2, 2020Mar 2, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 4, 2012First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT01511536 · 38 enrolled · United States, France, United Kingdom
  2. Jun 26, 2015Phase 4 study in Prostate Cancer MetastaticNCT02485691 · 255 enrolled · Austria, Belgium, Czechia and more

TargetBeta

CYP17A1 →read by rule
“Cytochrome P450 17A1 inhibitor”ChEMBL 37, by rule

Studies

All 2 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02485691Prostate Cancer Metastatic · Austria, Belgium, Czechia and more4CompletedMar 27, 2019255
NCT01511536Prostatic Neoplasms · United States, France, United Kingdom2CompletedJul 201438

How it is read

Names in the registry

  • “Abiraterone acetate”, 24 entries
  • “Abiraterone”, 10 entries
  • “Abiraterone Acetate”, 5 entries
  • “abiraterone acetate”, 2 entries
  • “Abiraterone acetate (Treatment B)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.